PMID: 8464046Apr 2, 1993Paper

Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate

Journal of Medicinal Chemistry
V M VrudhulaP M Wallace

Abstract

The syntheses and cytotoxic activities of substituted N-phenylacetamido derivatives of doxorubicin and melphalan are described. The derivatives were designed as prodrugs which could be activated in a site-specific manner by monoclonal antibody-penicillin-G amidase (mAb-PGA) conjugates. N-(Phenylacetamido)doxorubicin (2) and N-(phenylacetyl)melphalan (6) were found to be 10- and 20-fold less cytotoxic against H2981 lung adenocarcinoma cells than doxorubicin and melphalan, respectively. When incubated with PGA, the cytotoxicity of 2 and 6 increased and became equivalent to that of the corresponding drugs from which they were made. The poor solubility characteristics of 2 in aqueous solutions provided the basis for the development of the more soluble doxorubicin derivatives, N-(4-aminophenylacetyl)doxorubicin (3) and N-(4-phosphonooxy)phenylacetyl)-doxorubicin (4). In vitro cytotoxicity assays indicated that 3 and 4 were at least 1000-fold less toxic than doxorubicin against H2981 cells. PGA and the mAb conjugate L6-PGA were able to effect the activation of 3 and 6 on H2981 cells (L6-antigen positive). Hydrolysis of the phosphate group of 4 was required prior to activation with PGA or L6-PGA. This was achieved using alkaline phosp...Continue Reading

Citations

Mar 31, 2004·Bioorganic & Medicinal Chemistry·Neta PessahDoron Shabat
Oct 8, 1999·Pharmacology & Therapeutics·G M Dubowchik, M A Walker
Dec 18, 2001·Advanced Drug Delivery Reviews·P D Senter, C J Springer
Jul 7, 1997·Advanced Drug Delivery Reviews·C J Springer, I Niculescu-Duvaz
Jul 7, 1997·Advanced Drug Delivery Reviews·D J KerrI A McNeish
Oct 6, 1999·Current Opinion in Immunology·K D BagshaweR J Knox
Sep 1, 1995·Stem Cells·T A Connors, R J Knox
Jul 5, 2005·Expert Opinion on Investigational Drugs·K D BagshaweS K Sharma
Sep 1, 1996·International Journal of Oncology·B RettaE Enoamooquaye
Oct 27, 2004·Expert Opinion on Biological Therapy·Kenneth D BagshaweRichard H J Begent
Jun 15, 2007·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Sachin MittalGordon L Amidon
Nov 14, 2006·Biomolecular Engineering·Antonio De León-RodríguezAna P Barba de la Rosa
Dec 23, 2014·Medicinal Research Reviews·Herve Aloysius, Longqin Hu
Oct 16, 2016·Expert Opinion on Biological Therapy·Surinder K Sharma, Kenneth D Bagshawe
Oct 31, 2006·Expert Review of Anticancer Therapy·Kenneth D Bagshawe
Mar 6, 2004·Pharmacological Reviews·Martijn RooseboomNico P E Vermeulen
Jul 8, 1999·Journal of Medicinal Chemistry·I Niculescu-DuvazC J Springer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.